Theravance Biopharma (TBPH) CEO logs 20K-share tax withholding

Rhea-AI Filing Summary

Theravance Biopharma, Inc. (TBPH) reported that Chief Executive Officer and director Rick E. Winningham had 20,034 Ordinary Shares withheld on 2026-08-20 at $16.95 per share to satisfy tax obligations from the vesting of previously granted restricted stock units. The transaction was with the issuer and did not involve an open market trade. Following this tax-withholding disposition, he held 1,611,022 Ordinary Shares directly, plus 23,400 Ordinary Shares held indirectly as custodian and 92,567 Ordinary Shares held indirectly by a trust.

Insider Trade Summary

Net Seller: 20,034 shares

Net Sell 3 txns

Insider Winningham Rick E

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Ordinary Shares F1	20,034	$16.95	$340K
holding	Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Ordinary Shares — 1,611,022 shares (Direct); Ordinary Shares — 23,400 shares (Indirect, As Custodian); Ordinary Shares — 92,567 shares (Indirect, By Trust)

Footnotes (1)

1. F1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

Key Figures

Shares withheld for tax obligations: 20,034 Ordinary Shares Tax-withholding price per share: $16.95 per share Direct holdings after transaction: 1,611,022 Ordinary Shares +2 more

5 metrics

Shares withheld for tax obligations 20,034 Ordinary Shares Withheld on 2026-08-20 to satisfy tax obligations on RSU vesting

Tax-withholding price per share $16.95 per share Price used for the 20,034-share tax-withholding disposition

Direct holdings after transaction 1,611,022 Ordinary Shares Direct ownership by Rick E. Winningham after 2026-08-20 transaction

Indirect holdings as custodian 23,400 Ordinary Shares Indirect ownership classified as 'As Custodian' after the transaction

Indirect holdings by trust 92,567 Ordinary Shares Indirect ownership classified as 'By Trust' after the transaction

Key Terms

restricted stock units, open market transaction, withheld to satisfy tax obligations

3 terms

restricted stock units financial

"tax obligations arising out of the vesting of previously granted restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

open market transaction financial

"The share withholding transaction was with the issuer and did not involve an open market transaction"

An open market transaction is a buy or sell of publicly traded securities executed on an exchange or other public trading venue where many buyers and sellers can participate. It matters to investors because these trades change the visible supply and demand for a stock—like shoppers moving prices in a busy marketplace—affecting share price, liquidity (how easily you can trade), and sometimes the balance of ownership.

withheld to satisfy tax obligations financial

"Shares withheld to satisfy tax obligations arising out of the vesting"

FAQ

What insider transaction did TBPH CEO Rick Winningham report on August 20, 2026?

Rick E. Winningham reported a tax-withholding disposition of 20,034 Ordinary Shares of Theravance Biopharma, Inc. on 2026-08-20, at $16.95 per share, to satisfy tax obligations from the vesting of previously granted restricted stock units.

Was the August 20, 2026 TBPH insider transaction an open market sale?

No. The filing states the 20,034-share tax-withholding transaction was with the issuer and did not involve an open market transaction, as shares were withheld to satisfy tax obligations from restricted stock unit vesting.

How many TBPH shares does CEO Rick Winningham hold directly after this Form 4?

After the reported tax-withholding disposition, Rick E. Winningham held 1,611,022 Ordinary Shares of Theravance Biopharma, Inc. directly, according to the Form 4 data.

What are Rick Winningham’s indirect holdings of TBPH shares after the transaction?

After the transaction, Rick E. Winningham had 23,400 Ordinary Shares held indirectly as custodian and 92,567 Ordinary Shares held indirectly by a trust, in addition to his direct holdings.

What was the purpose of the 20,034 TBPH shares withheld on August 20, 2026?

The 20,034 Ordinary Shares were withheld to satisfy tax obligations arising from the vesting of previously granted restricted stock units, as disclosed in the Form 4 footnote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/24/2026 - 06:09 PM Accepted by SEC EDGAR 08/24/2026 - 06:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winningham Rick E

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/20/2026		F		20,034(1)	D	$16.95	1,611,022	D
Ordinary Shares								23,400	I	As Custodian
Ordinary Shares								92,567	I	By Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A Grimaud, Attorney-in-Fact	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)